Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
February 17 2021 - 08:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced that it
approved equity awards for 7 new employees with a grant date of
February 16, 2021 pursuant to Myovant’s 2020 Inducement Plan. The
equity awards were granted to the employees joining Myovant in
accordance with NYSE’s Listed Company Manual Rule 303A.08.
The new employees received, in the aggregate, restricted stock
units (RSUs) to purchase 30,000 common shares of Myovant.
One-fourth of the shares underlying each employee’s RSU will vest
on the one-year anniversary of the grant date, with the balance of
the common shares vesting in twelve equal quarterly installments
thereafter, in each case, subject to each such employee’s continued
employment with Myovant on such vesting dates. The RSUs are subject
to the terms and conditions of the 2020 Inducement Plan and the
applicable restricted stock unit agreements.
About Myovant Sciences Myovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. We have one FDA-approved medicine,
ORGOVYX™ (relugolix), for adult patients with advanced
prostate cancer. Our lead product candidate, relugolix combination
tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone
acetate 0.5 mg), is under regulatory review in Europe and
the U.S. for women with uterine fibroids and is under
development for women with endometriosis. We are also developing
MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has
completed a Phase 2a study for female infertility as part of
assisted reproduction. Sumitovant Biopharma, Ltd., a wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our
majority shareholder. For more information, please visit our
website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Investor Contact:Ryan CroweVice President,
Investor Relations Myovant Sciences, Inc.+1 (650)
781-9106investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.+1 (650)
410-3055media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2023 to Mar 2024